NanoVibronix, Inc. (NAOV)
- Previous Close
0.7500 - Open
0.7980 - Bid --
- Ask --
- Day's Range
0.7451 - 0.8025 - 52 Week Range
0.7000 - 4.3400 - Volume
33,415 - Avg. Volume
99,387 - Market Cap (intraday)
2.227M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1200 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.
www.nanovibronix.comRecent News: NAOV
Performance Overview: NAOV
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAOV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAOV
Valuation Measures
Market Cap
2.09M
Enterprise Value
-1.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.57
Price/Book (mrq)
0.52
Enterprise Value/Revenue
-0.52
Enterprise Value/EBITDA
0.34
Financial Highlights
Profitability and Income Statement
Profit Margin
-162.55%
Return on Assets (ttm)
-30.63%
Return on Equity (ttm)
-102.78%
Revenue (ttm)
2.28M
Net Income Avi to Common (ttm)
-3.71M
Diluted EPS (ttm)
-2.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
3.28M
Total Debt/Equity (mrq)
0.12%
Levered Free Cash Flow (ttm)
-1.79M